Tisagenlecleucel and axicabtagen-ciloleucel, the two CD19-targeting chimeric antigen receptor T cell therapies, have been successfully applied for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.